Latest news with #CitiusTech
Time of India
12-05-2025
- Business
- Time of India
Hunt for R&D talent picks up pace at health-tech, pharma firms
Pharmaceutical and health-tech firms are beefing up research and development teams, to enhance innovation, meet regulatory norms, including in overseas markets, extend capabilities in growth areas, and deliver high-quality, commercially-viable biosimilars across key therapeutic areas. #Operation Sindoor The damage done at Pak bases as India strikes to avenge Pahalgam Why Pakistan pleaded to end hostilities Kashmir's Pahalgam sparks Karachi's nightmare Firms like Lupin , Biocon Biologics, CitiusTech, Cipla , Dr Reddy's Laboratories, Sanofi, and Novartis are scaling up R&D teams, said industry officials and recruitment firms. Companies are focusing among other things, on research in cancer and targeted therapies, neurology, and rare and metabolic diseases. A key driver has been the surge in investments from private equity firms in pharma and health-tech firms, injecting not only capital, but also encouraging a greater focus on innovation and product development. Continue to video Virat Kohli announces retirement from Test cricket: '269 signing off' 5 5 Next Stay Closed captions (1) OFF Playback speed 1x Normal Quality Auto Back 360p 240p 144p Auto Back OFF English UK Back 0.25x 0.5x 1x Normal 1.5x 2x 5 5 / Skip Ads by Now Playing Virat Kohli announces retirement from Test cricket: '269 signing off' 02:36 Now Playing 'After 1000 years if...': Trump 'proud' of India-Pak ceasefire, 'will work on Kashmir solution' 02:59 Now Playing IAF confirms 'Operation Sindoor still ongoing' amid Pakistan's ceasefire violations 02:46 Now Playing US says deal struck to cut China trade deficit after two-day negotiation talk in Geneva 02:15 Now Playing Trump administration seeking to get first white South African refugees to US next week: NYT 01:44 Now Playing 'No more Souters': Republican Justice David Souter, who allied with Court's Liberal Wing, dies at 85 02:43 Now Playing First official video: Indian Army destroys Pakistan post across LoC in powerful retaliation 01:02 Now Playing From battlefield to begging bowl: Pak seeks global loans, later claims X account hacked 01:44 Now Playing Indian Brands In. International Luxe Out. Gen Z's New Shopping Code 00:49 Now Playing Introducing the ET Snapchat Gen Z Index: Your ultimate brand guide to understand Gen Z 01:19 Now Playing Gen Z Wants Work Flexibility — But Millennials Want It Even More! 00:39 Now Playing With ET Snapchat Gen Z Index, win Gen Z with data, not assumption 01:18 Now Playing Bold Online, Cautious with Money? Gen Z's Surprising Love for Fixed Deposits 00:33 Now Playing Gen Z Is Ditching Celebs — Here's Who They Trust Instead 00:38 Now Playing India-Pak Tension: PM Modi says 'Bharat ke haq ka paani, Bharat ke haq mein bahega...' 02:50 Now Playing 'As Defence Minister, I will give befitting reply': Rajnath Singh vows action after Pahalgam attack 01:38 Now Playing Israel's Netanyahu vows response against Yemen's Houthis after missile strike on Tel Aviv Airport 01:45 Now Playing Should you buy Titan? Technicals + jewellery sales point to upside 01:23 Now Playing 'Mexican president afraid of...': Trump offers US help to Mexico against cartels 01:34 Now Playing DRDO successfully conducts maiden flight-trial of stratospheric airship platform in Madhya Pradesh 02:14 Now Playing Warren Buffett to step down as CEO of Berkshire Hathaway, hands over leadership to Greg Abel 01:33 Now Playing Lavrov, Jaishankar hold talks on bilateral ties and rising tensions after Pahalgam terror attack 01:23 Now Playing 'Sovereignty Is Not For Sale': Mexican Prez Sheinbaum turns down Trump's troop offer against cartels 01:16 Now Playing 'We look for partners, not preachers': Jaishankar's message to Europe at Arctic Circle Forum 02:48 Now Playing Russia declares state of emergency at port after Ukrainian drone attack; 5 injured in Novorossiysk 01:56 Now Playing Donald Trump as Pope? White House shares US President's AI image in Papal attire 01:54 Now Playing Russian drones hit apartment block in Ukraine's Kharkiv, over 40 hurt 02:28 Now Playing Londoners reacts as Prince Harry loses legal fight over UK security 02:27 Now Playing 'It is never justified...': Families of judges who ruled against Trump faces threats on social media 02:37 Now Playing Australia PM Anthony Albanese casts vote amid cost-of-living crisis, uncertainty over Trump policies 01:40 Now Playing Trump's Education Department discontinues $1 billion grants to schools 02:32 Now Playing Trump designates Mike Waltz as next US Ambassador to UN, Rubio to be temporary NSA 01:10 Now Playing India closing airspace is a 'big problem' for Pak airlines, says ED, SAISA 01:00 Now Playing Japan: Man arrested for deliberately driving car into group of primary school kids 01:47 Now Playing 'Lunatic dumb guy...', Trump blasts Indian-origin US Congressman Thanedar over impeachment move 02:27 Now Playing Mass shooting incident in Sweden; 3 dead, several injured, probe underway 01:34 Now Playing Pak diplomacy touches new low, Pakistani official makes 'throat slit' gesture at London protesters 01:35 Now Playing Iran: Massive explosion at port city Bandar Abbas; 4 killed, over 500 injured 02:06 Now Playing Prime Minister of Norway meets Trump: 'No problems on trade issues at all' 01:56 Now Playing Xiaomi Photography Kit Quick Review | Tech Pulse 00:45 Now Playing Trump Deportation: Drone visuals of migrants at Texas detention facility 01:43 Now Playing Trump on his personal message to Putin: 'Vladimir stop!... 02:00 Now Playing Why is TVS Motor Company stock looking attractive on charts; time to buy? 01:11 Now Playing 'No intention of firing him': Trump on Fed Chair Powell 01:26 Now Playing Pope Francis Casket arrives at St Basilica 01:04 Now Playing JD Vance confirms finalisation of US, India terms of reference for trade 01:09 Now Playing Pahalgam attack: 'Asim Munir should sh*t in his pants', J&K ex-DGP Vaid slams Pak Army Chief 02:57 Now Playing Q4 Earnings Season Heats Up: Big Names to Watch This Week 01:20 Now Playing JD Vance's kids share adorable moments with PM Modi; Watch! 01:32 Now Playing PM Modi holds bilateral talks with US Vice President JD Vance in Delhi 01:28 Companies are also exploring applications of AI and machine learning in diagnostics, predictive analytics, and personalised care. Research in digital therapeutics , remote monitoring, and health platforms is also on the rise. Lupin is sharpening focus on complex generics and biosimilars, particularly in respiratory, injectables, and women's health. Live Events 'Our novel drug discovery programmes require specialised talent who can advance our research from early-stage development through to commercialisation. We're also investing in next-generation pharma technologies, including novel drug delivery systems and targeted therapies,' said Yashwant Mahadik, president – global human resources, Lupin. At Biocon Biologics, the R&D team plays a central role in driving innovation and delivering commercially viable, high-quality biosimilars across areas such as diabetes, oncology, ophthalmology, and autoimmune diseases. The company has several upcoming programmes in biosimilar product development which is fuelling the need for more R&D talent. 'We are hiring principal scientists, associate scientists, and research associates across various specialisations. These include candidates with Master's degrees in biotechnology, chemical engineering, as well as PhDs and post-doctoral researchers with experience in areas such as molecular biology, process development, analytical sciences, and regulatory sciences,' said a spokesperson. Their hiring strategy covers both lateral and campus hiring. CitiusTech is investing in healthcare informatics R&D. The firm is hiring for roles in generative AI, cloud and large-scale computing, and agentic AI — especially where they intersect with healthcare applications. Healthcare is transforming rapidly, and the adoption of digital technologies and agentic AI is opening up new possibilities for improving patient experience, clinical outcomes, and therapy research, said Sudhir Kesavan, COO, CitiusTech. Uptick in hiring The trend is echoed at recruitment firms like Adecco and Page Executive, which are seeing a sharp uptick in hiring for R&D roles, with compensation at the upper levels going up to Rs. 1-2 crore and above, depending on specialisation and seniority. Over the past year, Page Executive has seen a 15-20% rise in hiring for R&D roles across both pharma and health-tech sectors, with firms in oncology, AI diagnostics, and digital health experiencing the sharpest increase. 'We're seeing an uptick in Indian firms, along with multinational corporations, prioritising the expansion of their R&D teams, particularly by setting up global capability centres (GCCs) and research hubs within India,' said Nupur Mehta, partner at Page Executive. Firms are building capabilities in AI, data science, and regulatory affairs to enhance drug development and market readiness, and R&D hiring is central to driving innovation, ensuring compliance, and maintaining competitive advantage in a rapidly evolving healthcare landscape, said Karthikeyan K, director – permanent recruitment, Adecco India. 'We have seen a 20% increase in CXO hiring, 50% for junior to mid-levels, and about 35% in senior-level hiring. Specialised R&D talent remains limited, especially in high-demand areas like life sciences and advanced technologies, where deep expertise is required,' he added. Talent is being sourced from institutes like IISc, the IITs, NIPERs, and universities abroad, especially those known for life sciences, bioengineering, and medical research. Indian-origin researchers from abroad are also being encouraged to return to India, said hiring firms.
Forbes
26-03-2025
- Health
- Forbes
Generative AI In Healthcare: Innovation Amid Crises
Rajan Kohli, CEO of CitiusTech. Inspiring new possibilities for the health ecosystem with technology and human ingenuity. In conversations with healthcare executives and innovators across the healthcare industry, one sentiment echoes: Healthcare's challenges are as complex as its opportunities are vast. I have had leaders share stories of unrelenting pressure—from operational inefficiencies to skyrocketing patient demand—and how these are compounded by workforce shortages and the rising burden of chronic diseases. Technological innovators in the space race to develop solutions faster than regulations can adapt. Life sciences firms face spiraling R&D costs and a relentless demand for speed in drug discovery and clinical trials. But within these struggles, I believe generative AI has emerged as healthcare's most intriguing disruptor. Reports highlight generative AI's potential to cut R&D timelines, personalize patient engagement at scale and redefine clinical trial design with unprecedented speed and accuracy. It's moving beyond proof-of-concept into actionable transformation. With AI's applications in real-time transcription for electronic health records, automated claims processing and even AI-assisted diagnostics, generative AI is nudging the payer industry toward a more intelligent, agile future. In medtech, the technology is turning clinical workflows into intelligence-driven systems. Ambient listening converts clinician-patient conversations into structured data. In emergency rooms, GenAI can help prioritize cases in real time, enabling life-saving decisions. On top of this, automated billing can reduce delays, and clinical trial recruitment can align patient data with eligibility criteria. It's also revolutionizing drug discovery, research and clinical trials. Using advanced molecular analysis, generative AI can now create digital maps of chemical compounds, predicting interactions with unparalleled accuracy. 'Smart labs' are then able to analyze datasets, predict experimental outcomes and identify novel drug candidates. In clinical trials, generative AI integrates patient health records, genetic data and social factors to design more inclusive, real-world-representative studies. Real-time AI monitoring can flag adverse results early, mitigating risks and controlling costs. Lastly, generative AI is reshaping the provider landscape, delivering impact at every touchpoint. AI-powered diagnostics catch diseases earlier, and robotic surgical systems enhance accuracy. Wearable devices act as proactive health managers, continuously monitoring vital signs. Beyond clinical innovation, this technology can help simplify revenue cycles, automate processes and craft hyper-personalized wellness plans. This isn't just about efficiency or technology; it's a vision for a healthcare system that anticipates and meets patient needs while empowering providers to focus on delivering better outcomes. Yet, challenges like data and algorithmic bias demand countermeasures that include things like AI centers of excellence and fortified cybersecurity frameworks. The true power of GenAI lies in reshaping how payers build trust and deliver value. Data is the lifeblood of these applications of GenAI. However, transforming data into actionable intelligence remains a challenge that stifles innovation and progress. Too often, I see organizations set up foundational infrastructure only to lack bandwidth for the journey from insight to impact. The linear nature of this process delays value realization. Compounding this issue is what I see as an outdated reliance on business intelligence reports as the dominant channel for insight consumption. These static, often overloaded reports can slow decision cycles and constrain business users who must wait for analysts or automated processes to deliver the data they need. In a landscape where agility is everything, I think this method is no longer sustainable. On top of this, as healthcare shifts to cloud environments, costs can spiral. Therefore, organizations must balance scalability with financial discipline. AI-native infrastructures must support seamless transformations, real-time exploration and models that deliver new value. The goal is to refine, scale and deliver intelligence with precision. Organizations that align data with clear outcomes—ensuring readiness for GenAI—are the ones who will be best set up to unlock the transformative power of AI within their ecosystem. On top of the hurdles already outlined, ransomware attacks, data breaches and operational sabotage are rising, targeting interconnected healthcare systems. Healthcare data is unique, permanent and irreplaceable. Unlike financial records that can be reset, medical records are immutable, amplifying breach consequences. The digital sprawl, from wearable devices to AI diagnostics, expands the attack surface, making vigilance essential. As healthcare leaders address these challenges here are some of their approaches: 1. Modern cybersecurity is shifting to AI-powered frameworks for proactive defense. Extended detection and response (XDR) tools can analyze behavioral patterns, predicting and mitigating threats before escalation. 2. Ransomware attacks can paralyze operations, yet robust recovery strategies minimize impact. Resilience demands validated, immutable backups and swift recovery without data compromise. Align with business continuity planning (BCP) to ensure uninterrupted care delivery. 3. Streamlined digital identities minimize compliance gaps. Role-based access control (RBAC) and privileged access management (PAM) limit system access to authorized personnel, reducing risks. 4. As healthcare relies on application programming interfaces (APIs) for interoperability, safeguards must ensure minimal yet secure data sharing. Advanced data masking and encryption can further protect information during inter-system communication. 5. Predictive analytics, real-time threat detection and AI-driven incident response enable faster decision making and better risk management. Tailor your AI-driven managed detection and response (MDR) platforms for healthcare to enhance the protection of critical workflows and patient data. I believe healthcare is facing an existential reckoning that no app, algorithm or device alone can solve. Generative AI offers transformative potential, but only if paired with the infrastructure to turn data into decisions. Data strategies, in turn, are meaningless without robust cybersecurity to safeguard trust. Together, these trends reshape how care is delivered, operationalized and protected. Leaders must act decisively, invest wisely and design with purpose. The healthcare ecosystem will not transform through incrementalism—it demands bold vision and systemic alignment. Those who seize this moment will not only redefine their organizations but also set the standard for the future of healthcare. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Associated Press
20-03-2025
- Business
- Associated Press
PathPresenter Introduces ConsultConnect, a Zero Footprint Web Portal for Remote Second Opinions
AWS-powered solution enables institutions to scale their pathology remote second opinion programs globally MONTVILLE, NJ / ACCESS Newswire / March 20, 2025 / PathPresenter, a leader in digital pathology workflow software, is pleased to announce ConsultConnect, a new solution for digital pathology consultations and remote second opinions. Built by pathologists and powered by Amazon Web Services (AWS), ConsultConnect aims to provide leading institutions with the fastest, easiest, and most cost-effective way to scale their remote second opinion programs globally. Designed for institutions with significant subspecialty expertise, ConsultConnect addresses the two major barriers to adoption in digital pathology: budgeting and long implementation/integration times. First, ConsultConnect has no upfront implementation fees or subscription fees. Instead, there is a minimal annual commitment and simple 'per-consult' pricing. Second, ConsultConnect offers a highly streamlined and simplified onboarding process, allowing institutions to get up and running with their cloud-based solution in days instead of months. 'Digital pathology has long been viewed by institutions as an expense rather than an opportunity. At PathPresenter, we aim to shift that perspective by transforming digital pathology into a profit center while expanding institutions' global reach,' said Dr. Rajendra Singh, PathPresenter co-founder. 'With AWS's reliable infrastructure and PathPresenter's expertise, we empower our customers to bridge the gaps in their workflows, making digital pathology a seamless, scalable, and cost-effective solution.' ConsultConnect features all the tools required by pathologists and institution administrators to deliver remote second opinion services to referring hospitals globally. Core to the platform is a user-friendly, scanner-agnostic image viewer for pathologists to receive, view, and sign out remote second opinion cases. For administrators, the portal provides tools to easily onboard and manage referring hospitals and incoming cases. The zero-footprint platform is monitored 24/7 by industry-leading security and compliance vendor Vanta for HIPAA compliance. ConsultConnect has been optimized to run on AWS by PathPresenter and partner CitiusTech. With healthcare-focused expertise in medical imaging, CitiusTech leveraged AWS HealthImaging services to ensure ConsultConnect delivers the very best imaging performance and data integrity, including whole slide DICOM file upload functionality. AWS HealthImaging is a purpose-built, HIPAA-eligible service for medical imaging in the cloud, giving customers the performance, scale, and low total cost of ownership needed for large pathology workloads. AWS services provide robust security measures specifically designed for handling patient data across various healthcare entities. With AWS managed services, PathPresenter is providing low-latency, petabyte-scale digital pathology in the cloud. Early Adopter Program ConsultConnect will be available to select institutions through an early adopter program. For more information on this program and deploying ConsultConnect, see us at the USCAP Annual Meeting in Boston, MA, March 24-26 in booth 509, or visit About PathPresenter PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter's secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge. Learn more at Contact Details PathPresenter The PathPresenter Clinical Viewer is a digital pathology image viewing and management software. It is approved for research use only and has not been cleared by the FDA as a medical device. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using this device. Pathologists should exercise professional judgment in each clinical situation and examine the glass slides by conventional microscopy if there is doubt about the ability to accurately render an interpretation using this device alone.
